CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
To evaluate combination therapy of adding CTX-009 to the standard therapy GCD as first-line therapy in patients with unresectable or mBTC.
Epistemonikos ID: 269f11f686fd8ac9a31269dcd77f217225b7418b
First added on: Sep 01, 2024